Related Experiment Video
Updated: Jan 14, 2026
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
Antisense Oligonucleotide Therapy for Amyotrophic Lateral Sclerosis (ALS): An Umbrella Review
1College of Medicine, Choate Rosemary Hall, Farmington, USA.
Abstract:
Amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease, is a fatal neurodegenerative disease prominent in the elderly population. To this point, no completely effective treatments have been procured; however, antisense oligonucleotide therapies, or ASOs, are a promising venue. In order to investigate the efficacy of ASOs in the treatment of ALS by targeting specific genetic mutations, we conducted an umbrella review utilizing keywords such as "ALS" and "ASO" in the PubMed database, excluding sources published more than 10 years ago for relevance. Results revealed that of multiple tentative ASO treatments, for multiple specific gene mutations, only one, Tofersen, was approved for the wider population. The main cause of failure was an inability to meet efficacy endpoints, resulting in the discontinuation of the product. Tofersen is able to treat mutations in the SOD1 gene, but not any others. While initially discouraging, the production of ASOs is a relatively new and advanced process, and slow progress is expected. However, there remains the problem of identifying and treating the much more prevalent sporadic ALS, which is much more common compared to familial ALS.
Insights
Antisense oligonucleotide (ASO) therapies show promise for treating Amyotrophic Lateral Sclerosis (ALS). While Tofersen targets SOD1 mutations, developing effective ASOs for sporadic ALS remains a challenge.
Area of Science:
- Neurodegenerative Diseases
- Genetics
- Pharmacology
Background:
- Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's disease, is a fatal neurodegenerative condition.
- Current treatments for ALS are limited, highlighting the need for novel therapeutic approaches.
- Antisense oligonucleotide (ASO) therapies represent a promising avenue for targeting the genetic underpinnings of ALS.
Purpose of the Study:
- To investigate the efficacy of ASO therapies in treating ALS by targeting specific genetic mutations.
- To review recent advancements and challenges in ASO development for ALS.
Main Methods:
- An umbrella review of studies was conducted.
- PubMed database was searched using keywords "ALS" and "ASO".
- Studies published more than 10 years ago were excluded to ensure relevance.
Main Results:
- Multiple ASO candidates targeting various gene mutations were evaluated.
- Only Tofersen, targeting SOD1 gene mutations, received approval for broader use.
- Many ASO treatments failed to meet efficacy endpoints, leading to discontinuation.
- Sporadic ALS, which is more prevalent, remains difficult to target with current ASO strategies.
Conclusions:
- ASO therapy is a developing field with potential for ALS treatment, particularly for specific genetic forms like SOD1-mutated ALS.
- Significant challenges remain in developing effective ASOs for the majority of ALS cases, especially sporadic ALS.
- Continued research and development in ASO technology are crucial for advancing ALS treatment options.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:15Parkinson's Disease: Overview